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Abnormal regulation of tau phosphorylation and/or alternative splicing is associated with the development of a large (>20) group
of neurodegenerative disorders collectively known as tauopathies, the most common being Alzheimer’s disease. Despite intensive
research, little is known about the molecular mechanisms that participate in the transcriptional and posttranscriptional regulation
of endogenous tau, especially in neurons. Recently, we showed that mice lacking Dicer in the forebrain displayed progressive
neurodegeneration accompanied by disease-like changes in tau phosphorylation and splicing. Dicer is a key enzyme in the
biogenesis of microRNAs (miRNAs), small noncoding RNAs that function as part of the RNA-induced silencing complex (RISC)
to repress gene expression at the posttranscriptional level. We identiﬁed miR-16 and miR-132 as putative endogenous modulators
of neuronal tau phosphorylation and tau exon 10 splicing, respectively. Interestingly, these miRNAs have been implicated in
cell survival and function, whereas changes in miR-16/132 levels correlate with tau pathology in human neurodegenerative
disorders. Thus, understanding how miRNA networks inﬂuence tau metabolism and possibly other biological systems might
provide important clues into the molecular causes of tauopathies, particularly the more common but less understood sporadic
forms.
1.Introduction
The discovery of small noncoding miRNAs uncovered an
intriguing additional level to the ﬁne-tuning of the tran-
scriptome and proteome. Since their discovery almost 20
yearsago[1,2],researchhasprogressedconsiderablytowards
gaining a better understanding of the impact of the complex
networkofgeneregulationbymiRNAsonhealthanddisease.
This is well documented in the cancer ﬁeld, for instance,
where miRNAs are increasingly acknowledged as potential
diagnostic and therapeutic agents [3, 4]. Like protein-coding
genes,miRNAgenesaretranscribedfromthegenomemainly
from RNA polymerase II (reviewed in [5]). To date, more
than 1000 miRNA genes have been identiﬁed in humans
and 750 in mice, some of which are speciﬁcally expressed in
the brain [6–10]. In the cytoplasm, the endonuclease Dicer
cleaves miRNA precursors (approximately 70 nucleotides in
length) to generate mature (approximately 21 nucleotides in
length) double-stranded RNAs. These are loaded as single-
stranded RNAs into the RNA-induced silencing complex
(RISC),composedofArgonaute(Ago)proteins,tonegatively
regulate gene expression, albeit some exceptions have been
documented [11, 12]. This regulation is achieved through
binding with imperfect complementarity mainly to the 3
untranslated region (3UTR) of target messenger RNAs
(mRNAs), leading to translation inhibition or degradation.
Both in vitro and in vivo studies have shown that alterations
of a single miRNA (or miRNA family) could have profound
eﬀects on hundreds of target genes [13, 14], thus possibly
implicating multiple biological pathways.
Abnormal phosphorylation and insoluble deposition of
tau are observed in more than 20 neurodegenerative disor-
ders, collectively known as tauopathies (reviewed in [15]).
In Alzheimer’s disease (AD), the most common tauopathy,
hyperphosphorylated tau accumulates in the somatoden-
dritic compartment of neurons, aggregates, and ﬁnally forms2 International Journal of Alzheimer’s Disease
neuroﬁbrillary tangles (NFTs). Other tauopathies include
frontotemporal lobar degeneration (FTLD), Pick’s disease,
progressive supranuclear palsy (PSP), corticobasal degen-
eration (CBD), and progressive aphasia, all of which are
characterized by neuronal and/or glial tau inclusions.
Although the exact physiological role of tau remains
under scrutiny, it is proposed to function to promote micro-
tubule assembly, stabilization, spacing, and parallel-ordered
organization, which are necessary for axonal transport and
neurite outgrowth (reviewed in [16]). Tau binds to several
proteins(reviewedin[17])andthereforecouldparticipatein
various other paradigms, including targeting the Src kinase
Fyn to dendrites [18]. In the central nervous system, tau
is expressed as six isoforms, resulting from inclusion or
exclusion of alternative exons 2, 3, and 10 [19]( r e v i e w e di n
[20]).Mutationsinorsurroundingtauexon10,leadingtoan
imbalance in tau isoforms with 3 or 4 microtubule-binding
domains, can cause familial FTLD-17. Thus, tau missplicing
can cause neurodegeneration and dementia in adulthood.
Changes in tau isoforms have also been observed in various
other tauopathies, including PSP and Pick’s disease or
myotonic dystrophy (reviewed in [21]); however, the under-
lying mechanisms involved in abnormal tau splicing and
neurodegeneration remain ill-deﬁned. Moreover, whether
splicing abnormalities function upstream or concomitantly
with tau hyperphosphorylation to promote neurodegenera-
tion remains an open debate.
To date, several groups have identiﬁed factors involved
in the regulation of tau splicing. These include regulatory
sequences (cis-elements) within or around tau exon 10 as




based on artiﬁcial and/or overexpression paradigms, which
makesitdiﬃculttoextrapolatetheseobservationstoendoge-
nous tau.
In 2006, Bilen et al. [23] showed a remarkable enhance-
ment of tau-mediated cell death in Drosophila cells upon
suppression of miRNA maturation. Speciﬁcally, the authors
showed that retinal degeneration caused by the expression of
normalormutant(R406W)humantauinvivowasenhanced
by loss of R3D1/loquacious, a double-stranded RNA binding
proteinthatisrequiredfortheactivityofDcr-1(Dicerhomo-
logue) in miRNA processing. Interestingly, upregulation of
bantam suppressed tau-induced degeneration, suggesting
that this miRNA could mitigate tau-induced neurotoxicity.
However, as bantam is not conserved in humans, it is
tempting to speculate that other miRNAs play a similar role
in the mammalian brain. More recently, a neuronal miRNA,
miR-128, was shown to modulate the expression of BAG2,
a cochaperone potentially involved in tau degradation and
aggregation in cultured COS-7 cells and in primary neurons
[24]. Our recently published data indicate that conditional
knockout (cKO) of Dicer (resulting in a global reduction
in miRNA production) in the adult mouse brain results in
disease-like hyperphosphorylation of endogenous tau [25].
Moreover, the Dicer mutant mice display changes in tau exon
10 splicing [26], as seen in various tauopathies including
PSP and Pick’s disease. In this paper, we highlight salient
observations with regard to these studies and highlight out-
standingquestionsrelatedtomiRNAresearchintauopathies.
2. Tau Phosphorylation Regulation by
the miR-15 Family
Tauisaphosphoproteinthatcontainsmorethan80potential
phosphorylation sites (reviewed in [27]). It is generally
well accepted that tau phosphorylation is important for
microtubule binding, whereas phosphorylation causes tau to
detach from microtubules. Hyperphosphorylation, deﬁned
as increased phosphorylation of physiological sites and addi-
tional phosphorylation at pathological sites, characterizes
insoluble aggregates of tau. However, in its unphosphory-
lated form, under thermal stress, tau localizes to the nucleus,
where it protects DNA from double-stranded DNA damage
[28]. A phosphorylated pool of tau could also localize
to somatodendritic compartment as well as the dendritic
spine to modulate neuronal plasticity and glutamatergic
transmission [18]. Tau phosphorylation is very sensitive
to intrinsic and extrinsic changes (e.g., heat, cold, stress,
and starvation) [29–32]. Thus, any changes in the delicate
balancebetweenthetaukinasesandphosphatasescouldhave
serious biological consequences, and the identiﬁcation of
these regulatory enzymes in vivo is of particular importance.
It is noteworthy that some of those central key kinases also
regulate indirectly tau splicing through phosphorylation of
splicing factors [33–36]. Together, deregulation of kinase
and/or phosphatase activity could be dually detrimental
towards tau splicing and phosphorylation, which synergis-
tically would promote tau aggregation.
As general posttranslational regulation of gene expres-
sion, miRNAs are potential modulators of kinase, phos-
phatase, and/or splicing factor expression. While studying
the eﬀects of Dicer loss in the brain, we observed signiﬁcant
changes in endogenous tau phosphorylation and splicing
[26]. This was demonstrated at the RNA and protein
levels using, RT-PCR, 2D electrophoresis and tau phospho-
speciﬁc antibodies. Because of using the Cre-LoxP system,
Dicer inactivation was limited to neurons, and in particular
postmitotic pyramidal neurons. It is noteworthy that only
a few studies have documented changes in endogenous tau
phosphorylation in vivo,a sm o s tb i o l o g i c a lm o d e l se x p r e s s
exogenous and/or mutated human tau. Remarkably, several
phosphoepitopes related to disease, including serine 422,
were increased in the Dicer mutant mice when compared
with controls [25]. Unfortunately, given the rather quick
lethality associated with Dicer loss (approximately 4 weeks),
we could not determine whether tau hyperphosphorylation
concurred before or after neurodegeneration. Nevertheless,
theseresultsprovideaproofofconceptthatmiRNAhaploin-
suﬃciency causes abnormal tau hyperphosphorylation and
missplicing.
As stated above, several tau kinases and phosphatases
have been identiﬁed, some of which are believed to con-
tribute signiﬁcantly to tau hyperphosphorylation in vivo.
In attempt to identify such enzymes in the Dicer cKO

































miRNA downregulated in progressive supranuclear palsy
miRNA downregulated in Alzheimer’s disease
(b) Alternative splicing regulation
Figure 1: Potential role of miRNAs in tau metabolism regulation. (a, b) Two models are shown demonstrating how speciﬁc miRNAs could
be involved in the regulation of tau phosphorylation (and aggregation) and/or tau exon 10 alternative splicing. Note that some miRNAs are
aﬀected in disease conditions (in green, downregulated in AD; in red, downregulated in PSP). Whether other miRNA target eﬀectors are
involved in the physiological and/or pathological regulation of tau metabolism remains to be explored. Any changes in the level or function
of these miRNAs could have serious biological consequences, including tau hyperphosphorylation and aggregation and an imbalance in
tau microtubule-binding repeats (encoded in tau exon 10, giving rise to either four 4R-tau or 3R-tau). Regulation of tau exon 10 splicing
by PTBP1 or PTBP2 may be direct or may implicate other coregulators such as TDP-43 or PSF, both of which have been shown to either
regulate PTBP2 expression or regulate PTBP splicing and repress tau exon 10 inclusion [26, 52–54].
blot analyses. These experiments led to the identiﬁcation
of ERK1/MAPK3 (and possibly ERK2/MAPK1) as a major
regulator of neuronal tau phosphorylation in vivo,a tl e a s t
in this model. In line with this observation, several ERK1-
dependent epitopes were hyperphosphorylated in the Dicer
mutant mice. Of course, several other enzymes can poten-
tiallycontributetotauphosphorylationmisregulationinthis
and other models, and in particular disease conditions in
humans. In line with this hypothesis, a number of proposed
tau kinases, including GSK3β and JNK/MAPK8, are prone to
miRNA regulation in various cell types [37, 38]. Neverthe-
less, it is interesting to observe that ERK phosphorylation is
increased in tau-positive neurons in AD and other tauopa-
thies[39–41].Inaddition,ERKisessentialforbraindevelop-
ment and involved in neuronal death [42, 43]. Speciﬁc gene
knockout mouse models are required to assess the role of
these proteins in the regulation of tau phosphorylation and
neurodegeneration in vivo.
Although it is a conceptually crude experimental
approach,theDicercKOmiceprovideauniqueandunbiased
model to study global miRNA function in the brain. To
identify miRNAs involved in the regulation of ERK1 (and
consequently tau phosphorylation), we used several predic-
tion programs that are available online, including TargetScan
(http://targetscan.org/).Thisprogramidentiﬁedanumberof
potential miRNA-binding sites in the 3U T Ro fE R K 1 .O u r
functional assays provided the validation that several mem-
bers of the miR-16 family (miR-16, -15, -195, -497) could
directly modulate endogenous ERK1 and tau phosphoryla-
tion in neuronal cellsinvitro, including ratprimary neurons.
Of mention, both endogenous miR-16 and tau are enriched
in distal axons of sympathetic neurons [44]. Intriguingly,
miR-15a and miR-15b are downregulated in AD brain and
cerebrospinal ﬂuid, respectively [25, 45, 46], providing
clinical relevance for these observations. Moreover, miR-15
targets the proapoptotic protein Bcl-2, whose protein levels
are increased in AD [47–49]. In addition, miR-16 overex-
pression could regulate APP expression in vivo in the mouse
brain [50]. Taken together, these observations highlight the
potential importance of the miR-16 family in AD develop-
mentbyregulatingcellsurvival,amyloidproduction,andtau
phosphorylation (Figure 1). Interestingly, TargetScan pre-
dicts more than 1000 human target genes for miR-16, several
of which are associated with networks related to cell death,
cellular organization, and molecular transport (S. S. H´ ebert,
unpublishedobservations).Notably,amongthehigh-scoring
predicted targets are miRNA-processing regulators such as
TNRC6B [51]. It will be interesting to see whether loss of
miR-16 family members in vivo recapitulates, at least in past,




As discussed above, abnormal regulation of tau exon 10
splicing can cause disease. It is interesting to note that Dicer
deﬁciency in the adult brain is also associated with changes
in tau splicing [26]. Using a similar strategy as above (e.g.,
bioinformatics, microarrays, literature search, western blot4 International Journal of Alzheimer’s Disease
analysis, etc.), we identiﬁed miR-132 and the neuronal splic-
ing regulator PTBP2 as potential regulators of endogenous
tau exon 10 splicing in neurons. These results are consistent
withpreviousﬁndingslinkingtauexon10splicingregulation
by PTBP1 in vitro [55].
Whilenotdiscussedindetailinourstudy,othermiRNAs,
including miR-124 and miR-9, could also regulate endoge-
nous tau exon 10 splicing in neuronal cells by targeting
speciﬁcregulatoryand/orsplicingfactors[26].BothmiRNAs
are downregulated in AD [56–58], which could have impor-
tant consequences for tau metabolism, at least in certain
biological contexts (Figure 1). For instance, downregulation
of miR-9 is observed in the presence of exogenous Aβ in
mouseprimaryneurons[59].WhetherthisorothermiRNAs
function as intermediates between Aβ peptides, tau missplic-
ingandhyperphosphorylationremainanexcitingpossibility.
Interestingly, diﬀerential splicing of the tau transcript has
also been reported in AD [60, 61].
PSP is a cause of late-onset atypical parkinsonism
described by Steele et al. [62]. Dementia is also a common
feature at the end stage of the disease. Neuropathologically,
PSP is characterized by neuronal loss, gliosis, and NFT
formation. Glial ﬁbrillary tangles have also been described.
In these patients, tau aggregates are mainly composed of
tau with 4 microtubule-binding domains (4R-tau) [13,
15]. Using PSP as a model disease, we identiﬁed miR-132
to be selectively downregulated in pathological condi-
tions. Interestingly, PTBP2 protein (but not mRNA) levels
were increased in PSP patients and correlated signiﬁcantly
with miR-132 expression [26]. These experiments provide
unprecedented molecular links among abnormal tau splic-
ing, hyperphosphorylation, and sporadic tauopathies. Inter-
estingly, changes in PTBP1 and PTBP2 levels, and by exten-
sion alternative splicing patterns, have been documented
in human diseases, including neurodegenerative disorders
[63, 64]. On the basis of these observations, it is tempting
to speculate that miRNAs could contribute signiﬁcantly to
several aspects of tau metabolism and neuronal dysfunction
in various diseases.
4. OutstandingQuestions
Although the above-mentioned studies are interesting, many
questions remain unanswered. For instance, what are the
biological and clinical signiﬁcance of these ﬁndings? Are
other miRNAs involved in tau metabolism regulation? Can
miRNAs be used as diagnostic and possibly therapeutic
agents for sporadic tauopathies? Without a doubt, these and
other questions will require extensive followup studies in
various models, from cells to animals to humans.
Abbreviation
3UTR: 3 Untranslated region.
Conﬂict of Interests
The authors declared that there is no conﬂict of interests.
Acknowledgments
This work was supported by the Alzheimer Society of
Canada, the French National Research Agency, and the
Research on Alzheimer’s Disease and Related Disorders
Qu´ ebec-France-Canada Collaboration grant (TAUMIRNA).
This work has been developed through the LABEX (Labo-
ratories of Excellence, investing for the future program) and
DISTALZ (Development of Innovative Strategies for a Trans-
disciplinary Approach to Alzheimer’s Disease).
References
[ 1 ]R .C .L e e ,R .L .F e i n b a u m ,a n dV .A m b r o s ,“ T h eC .e l e g a n s
heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854,
1993.
[2] R. Lee, R. Feinbaum, and V. Ambros, “A short history of a
short RNA,” Cell, vol. 116, pp. S89–S92, 2004.
[3] L. Ma and R. A. Weinberg, “Micromanagers of malignancy:
role of microRNAs in regulating metastasis,” Trends in Genet-




[5] S. S. H´ ebert and B. de Strooper, “Alterations of the microRNA
network cause neurodegenerative disease,” Trends in Neuro-
sciences, vol. 32, no. 4, pp. 199–206, 2009.
[6] E. A. Miska, E. Alvarez-Saavedra, M. Townsend et al., “Mi-
croarray analysis of microRNA expression in the developing
mammalianbrain,”GenomeBiology,vol.5,no.9,p.R68,2004.
[ 7 ]O .B a r a d ,E .M e i r i ,A .A v n i e le ta l . ,“ M i c r o R N Ae x p r e s s i o n
detectedbyoligonucleotidemicroarrays:systemestablishment
and expression proﬁling in human tissues,” Genome Research,
vol. 14, no. 12, pp. 2486–2494, 2004.
[8] L. F. Sempere, S. Freemantle, I. Pitha-Rowe, E. Moss, E.
Dmitrovsky, and V. Ambros, “Expression proﬁling of mam-
malian microRNAs uncovers a subset of brain-expressed
microRNAs with possible roles in murine and human neu-
ronal diﬀerentiation,” Genome biology, vol. 5, no. 3, p. R13,
2004.
[ 9 ]N .Y .S h a o ,H .Y .H u ,Z .Y a ne ta l . ,“ C o m p r e h e n s i v es u r v e yo f
humanbrainmicroRNAbydeepsequencing,”BMCGenomics,
vol. 11, p. 409, 2010.
[10] J. E. Babiarz, R. Hsu, C. Melton, M. Thomas, E. M. Ullian,
and R. Blelloch, “A role for noncanonical microRNAs in the
mammalian brain revealed by phenotypic diﬀerences in Dgcr8
versus Dicer1 knockouts and small RNA sequencing,” RNA,
vol. 17, no. 8, pp. 1489–1501, 2011.
[11] S.Vasudevan,Y.Tong,andJ.A.Steitz,“Switchingfromrepres-
sion to activation: microRNAs can up-regulate translation,”
Science, vol. 318, no. 5858, pp. 1931–1934, 2007.
[12] R. F. Place, L. C. Li, D. Pookot, E. J. Noonan, and R. Dahiya,
“MicroRNA-373 induces expression of genes with comple-
mentary promoter sequences,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 105,
no. 5, pp. 1608–1613, 2008.
[13] D. Baek, J. Vill´ en, C. Shin, F. D. Camargo, S. P. Gygi, and D. P.
Bartel,“TheimpactofmicroRNAsonproteinoutput,”Nature,
vol. 455, no. 7209, pp. 64–71, 2008.
[14] M. Selbach, B. Schwanh¨ ausser, N. Thierfelder, Z. Fang, R.
Khanin, and N. Rajewsky, “Widespread changes in proteinInternational Journal of Alzheimer’s Disease 5
synthesis induced by microRNAs,” Nature, vol. 455, no. 7209,
pp. 58–63, 2008.
[15] L. Bu´ ee, T. Bussi` ere, V. Bu´ ee-Scherrer, A. Delacourte, and P.
R. Hof, “Tau protein isoforms, phosphorylation and role in
neurodegenerative disorders,” Brain Research Reviews, vol. 33,
no. 1, pp. 95–130, 2000.
[16] M. Morris, S. Maeda, K. Vossel, and L. Mucke, “The Many
faces of tau,” Neuron, vol. 70, no. 3, pp. 410–426, 2011.
[17] R. Brandt and J. Leschik, “Functional interactions of tau and
their relevance for Alzheimer’s disease,” Current Alzheimer
Research, vol. 1, no. 4, pp. 255–269, 2004.
[18] L. M. Ittner, Y. D. Ke, F. Delerue et al., “Dendritic function of
tau mediates amyloid-β toxicity in Alzheimer’s disease mouse
models,” Cell, vol. 142, no. 3, pp. 387–397, 2010.
[19] P. J. Chapple, K. Anthony, T. R. Martin, A. Dev, T. A. Cooper,
and J. M. Gallo, “Expression, localization and tau exon 10
splicing activity of the brain RNA-binding protein TNRC4,”
Human Molecular Genetics, vol. 16, no. 22, pp. 2760–2769,
2007.
[20] A. Andreadis, “Tau gene alternative splicing: expression pat-
terns, regulation and modulation of function in normal brain
and neurodegenerative diseases,” Biochimica Et Biophysica
Acta, vol. 1739, no. 2, pp. 91–103, 2005.
[21] N. Sergeant, A. Bretteville, M. Hamdane et al., “Biochemistry
of Tau in Alzheimer’s disease and related neurological disor-




ical Society Transactions, vol. 38, no. 4, pp. 967–972, 2010.
[23] J. Bilen, N. Liu, B. G. Burnett, R. N. Pittman, and N.
M. Bonini, “MicroRNA pathways modulate polyglutamine-
induced neurodegeneration,” Molecular Cell,v o l .2 4 ,n o .1 ,p p .
157–163, 2006.
[24] D. C. Carrettiero, I. Hernandez, P. Neveu, T. Papagian-
nakopoulos, and K. S. Kosik, “The cochaperone BAG2 sweeps
paired helical ﬁlament-insoluble tau from the microtubule,”
Journal of Neuroscience, vol. 29, no. 7, pp. 2151–2161, 2009.
[25] S.S.H´ ebert,A.S.Papadopoulou,P.Smithetal.,“Geneticabla-
tion of Dicer in adult forebrain neurons results in abnormal
tau hyperphosphorylation and neurodegeneration,” Human
Molecular Genetics, vol. 19, no. 20, pp. 3959–3969, 2010.
[26] P. Y. Smith, C. Delay, J. Girard et al., “MicroRNA-132 loss is
associated with tau exon 10 inclusion in progressive supranu-
clear palsy,” Human Molecular Genetics, vol. 20, no. 20, pp.
4016–4024, 2011.
[27] D. P. Hanger and W. Noble, “Functional implications of
glycogen synthase kinase-3-mediated tau phosphorylation,”
International Journal of Alzheimer’s Disease, vol. 2011, Article
ID 352805, 11 pages, 2011.
[28] A. Sultan, F. Nesslany, M. Violet et al., “Nuclear Tau, a key
player in neuronal DNA protection,” Journal of Biological
Chemistry, vol. 286, no. 6, pp. 4566–4575, 2011.
[29] R. A. Whittington, M. A. Papon, F. Chouinard, and E. Planel,
“Hypothermia and Alzheimer’s disease neuropathogenic
pathways,” Current Alzheimer Research, vol. 7, no. 8, pp. 717–
725, 2010.
[30] E. Planel, A. Bretteville, L. Liu et al., “Acceleration and per-
sistence of neuroﬁbrillary pathology in a mouse model of tau-
opathy following anesthesia,” The FASEB Journal, vol. 23, no.
8, pp. 2595–2604, 2009.
[31] Y. Okawa, K. Ishiguro, S. C. Fujita, and J. Avila, “Stress-
induced hyperphosphorylation of tau in the mouse brain,”
FEBS Letters, vol. 535, no. 1–3, pp. 183–189, 2003.
[32] M. Yanagisawa, E. Planel, K. Ishiguro, and S. C. Fujita, “Star-
vation induces tau hyperphosphorylation in mouse brain:
implications for Alzheimer’s disease,” FEBS Letters, vol. 461,
no. 3, pp. 329–333, 1999.
[33] W. Qian, H. Liang, J. Shi et al., “Regulation of the alternative
splicing of tau exon 10 by SC35 and Dyrk1A,” Nucleic Acids
Research, vol. 39, no. 14, pp. 6161–6171, 2011.
[34] J. Shi, W. Qian, X. Yin et al., “Cyclic AMP-dependent protein
kinase regulates the alternative splicing of tau exon 10: a
mechanism involved in tau pathology of Alzheimer disease,”
Journal of Biological Chemistry, vol. 286, no. 16, pp. 14639–
14648, 2011.
[35] D. C. Glatz, D. Rujescu, Y. Tang et al., “The alternative splicing
of tau exon 10 and its regulatory proteins CLK2 and TRA2-
BETA1 changes in sporadic Alzheimer’s disease,” Journal of
Neurochemistry, vol. 96, no. 3, pp. 635–644, 2006.
[36] F. Hern´ andez, M. P´ erez, J. J. Lucas, A. M. Mata, R. Bhat, and
J. Avila, “Glycogen synthase kinase-3 plays a crucial role in
tau exon 10 splicing and intranuclear distribution of SC35:
implications for Alzheimer’s disease,” Journal of Biological
Chemistry, vol. 279, no. 5, pp. 3801–3806, 2004.
[37] J. S. Mohamed, M. A. Lopez, and A. M. Boriek, “Mechani-
cal stretch up-regulates microRNA-26a and induces human
airway smooth muscle hypertrophy by suppressing glycogen
synthase kinase-3β,” Journal of Biological Chemistry, vol. 285,
no. 38, pp. 29336–29347, 2010.
[38] Z. Yang, S. Chen, X. Luan et al., “MicroRNA-214 is aberrantly
expressed in cervical cancers and inhibits the growth of hela
cells,” IUBMB Life, vol. 61, no. 11, pp. 1075–1082, 2009.
[39] I. Ferrer, R. Blanco, M. Carmona et al., “Phosphorylated map
kinase (ERK1, ERK2) expression is associated with early tau
deposition in neurones and glial cells, but not with increased
nuclear DNA vulnerability and cell death, in Alzheimer
disease, Pick’s disease, progressive supranuclear palsy and
corticobasal degeneration,” Brain Pathology, vol. 11, no. 2, pp.
144–158, 2001.
[40] K. Iqbal, C. Alonso Adel, E. El-Akkad et al., “Signiﬁcance and
mechanism of Alzheimer neuroﬁbrillary degeneration and
therapeutic targets to inhibit this lesion,” Journal of Molecular
Neuroscience, vol. 19, no. 1-2, pp. 95–99, 2002.
[41] G. Perry, H. Roder, A. Nunomura et al., “Activation of neu-
ronal extracellular receptor kinase (ERK) in Alzheimer disease
links oxidative stress to abnormal phosphorylation,” NeuroRe-
port, vol. 10, no. 11, pp. 2411–2415, 1999.
[42] Y. Satoh, Y. Kobayashi, A. Takeuchi, G. Pag` es, J. Pouyss´ egur,
and T. Kazama, “Deletion of ERK1 and ERK2 in the CNS
causes cortical abnormalities and neonatal lethality: Erk1
deﬁciency enhances the impairment of neurogenesis in Erk2-
deﬁcient mice,” Journal of Neuroscience,v o l .3 1 ,n o .3 ,p p .
1149–1155, 2011.
[43] S. Subramaniam and K. Unsicker, “ERK and cell death:
ERK1/2 in neuronal death,” The FEBS Journal, vol. 277, no.
1, pp. 22–29, 2010.
[44] O. Natera-Naranjo, A. Aschraﬁ, A. E. Gioio, and B. B.
Kaplan, “Identiﬁcation and quantitative analyses of microR-
NAs located in the distal axons of sympathetic neurons,” RNA,
vol. 16, no. 8, pp. 1516–1529, 2010.
[45] J. P. Cogswell, J. Ward, I. A. Taylor et al., “Identiﬁcation
of miRNA changes in Alzheimer’s disease brain and CSF
yieldsputativebiomarkersandinsightsintodiseasepathways,”
Journal of Alzheimer’s Disease, vol. 14, no. 1, pp. 27–41, 2008.
[46] J. Nunez-Iglesias, C.-C. Liu, T. E. Morgan, C. E. Finch, and
X. J. Zhou, “Joint genome-wide proﬁling of miRNA and6 International Journal of Alzheimer’s Disease
mRNA expression in Alzheimer’s disease cortex reveals altered
miRNA regulation,” PloS One, vol. 5, no. 2, p. e8898, 2010.
[47] A. Cimmino, G. A. Calin, M. Fabbri et al., “MiR-15 and miR-
16 induce apoptosis by targeting BCL2,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 102, no. 39, pp. 13944–13949, 2005.
[ 4 8 ]G .L u ,W .H .K w o n g ,Q .L i ,X .W a n g ,Z .F e n g ,a n dD .T .Y e w ,
“Bcl2, bax, and nestin in the brains of patients with neurode-
generation and those of normal aging,” Journal of Molecular
Neuroscience, vol. 27, no. 2, pp. 167–174, 2005.
[49] K. L. Jordan-Sciutto, L. M. Malaiyandi, and R. Bowser,
“Altered distribution of cell cycle transcriptional regulators
during Alzheimer disease,” Journal of Neuropathology and
Experimental Neurology, vol. 61, no. 4, pp. 358–367, 2002.
[50] W. Liu, C. Liu, J. Zhu et al., “MicroRNA-16 targets amy-
loid precursor protein to potentially modulate Alzheimer’s-
associated pathogenesis in SAMP8 mice,” Neurobiology of
Aging, vol. 33, pp. 522–534, 2012.
[51] J. T. Zipprich, S. Bhattacharyya, H. Mathys, and W. Filipowicz,
“Importance of the C-Terminal domain of the human GW182
protein TNRC6C for translational repression,” RNA, vol. 15,
no. 5, pp. 781–793, 2009.
[52] P. Ray, A. Kar, K. Fushimi, N. Havlioglu, X. Chen, and J.
Y. Wu, “PSF suppresses tau exon 10 inclusion by interacting
with a stem-loop structure downstream of exon 10,” Journal of
Molecular Neuroscience, vol. 45, no. 3, pp. 453–466, 2011.
[53] C. F. Sephton, C. Cenik, A. Kucukural et al., “Identiﬁcation of
neuronal RNA targets of TDP-43-containing ribonucleopro-
tein complexes,” Journal of Biological Chemistry, vol. 286, no.
2, pp. 1204–1215, 2011.
[54] M. L. Wei, J. Memmott, G. Screaton, and A. Andreadis, “The
splicing determinants of a regulated exon in the axonal MAP
tau reside within the exon and in its upstream intron,” Molec-
ular Brain Research, vol. 80, no. 2, pp. 207–218, 2000.
[ 5 5 ]J .W a n g ,Q .S .G a o ,Y .W a n g ,R .L a f y a t i s ,S .S t a m m ,a n dA .
Andreadis,“Tauexon10,whosemissplicingcausesfrontotem-
poral dementia, is regulated by an intricate interplay of cis
elements and trans factors,” Journal of Neurochemistry, vol. 88,
no. 5, pp. 1078–1090, 2004.
[56] S. S. H´ ebert, K. Horr´ e, L. Nicola¨ ı et al., “Loss of microRNA
cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates
with increased BACE1/β-secretase expression,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 105, no. 17, pp. 6415–6420, 2008.
[57] P. Smith, A. Al Hashimi, J. Girard, C. Delay, and S. S. H´ ebert,
“In vivo regulation of amyloid precursor protein neuronal
splicing by microRNAs,” Journal of Neurochemistry, vol. 116,
no. 2, pp. 240–247, 2011.
[58] W. J. Lukiw, “Micro-RNA speciation in fetal, adult and
Alzheimer’s disease hippocampus,” Neuroreport,v o l .1 8 ,n o .3 ,
pp. 297–300, 2007.
[59] N. Schonrock, Y. D. Ke, D. Humphreys et al., “Neuronal
microRNA deregulation in response to Alzheimer’s disease
amyloid-β,” PloS one, vol. 5, no. 6, p. e11070, 2010.
[60] K.Y asojima,E.G.M cGeer ,andP .L.M cGeer ,“T angledar easof
Alzheimer brain have upregulated levels of exon 10 containing
tau mRNA,” Brain Research, vol. 831, no. 1-2, pp. 301–305,
1999.
[61] T. M. Caﬀrey, C. Joachim, S. Paracchini, M. M. Esiri, and R.
Wade-Martins, “Haplotype-speciﬁc expression of exon 10 at
the human MAPT locus,” Human Molecular Genetics, vol. 15,
no. 24, pp. 3529–3537, 2006.
[62] J. C. Steele, J. C. Richardson, and J. Olszewski, “Progressive
supranuclear palsy. A heterogeneous degeneration involving
the brain stem, basal ganglia and cerebellum with vertical
gaze and pseudobulbar palsy, nuchal dystonia and dementia,”
Archives of Neurology, vol. 10, pp. 333–359, 1964.
[63] J. R. Tollervey, Z. Wang, T. Hortob´ agyi et al., “Analysis of alter-
native splicing associated with aging and neurodegeneration
in the human brain,” Genome Research, vol. 21, no. 10, pp.
1572–1582, 2011.
[64] T. Sterne-Weiler, J. Howard, M. Mort, D. N. Cooper, and J. R.
Sanford, “Loss of exon identity is a common mechanism of
human inherited disease,” Genome Research, vol. 21, no. 10,
pp. 1563–1571, 2011.